Aerosol immunisation for TB: Matching route of vaccination to route of infection

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 109, Issue 3, 2014, Pages 175-181

  Thomas, Zita Rose Manjaly ^a   McShane, Helen ^a  

^a Churchill Hospital   (United Kingdom)

Author keywords

Aerosol; Tuberculosis; Vaccination; Vaccines

Indexed keywords

BCG VACCINE; INFLUENZA VACCINE; MEASLES VACCINE; AEROSOL; IMMUNOLOGICAL ADJUVANT;

AEROSOL; ARTICLE; BACTERIAL TRANSMISSION; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLUENZA; INFLUENZA VACCINATION; MEASLES; MEASLES VACCINATION; NONHUMAN; TUBERCULOSIS; IMMUNIZATION; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; PROCEDURES; TUBERCULOSIS, PULMONARY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INHALATION; AEROSOLS; BCG VACCINE; HUMANS; IMMUNIZATION; TUBERCULOSIS, PULMONARY;

EID: 84928882493     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/tru206     Document Type: Article

References (87)

1. WHO. Global tuberculosis report 2013. Geneva: World Health Organization; 2013.
2. NICE. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. National Institute for Health and Care Excellence; 2011.
3. HPA. Tuberculosis in the UK. Health Protection Agency annual report; 2011. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/ Tuberculosis/ [accessed December 2014].
4. Dye C, Scheele S, Dolin P et al. Consensus statement. Consensus statement 1999;282:677-86.
5. WHO. Multidrug and extensively drug-resistant TB (M/XDR TB):2010 global report on surveillance and response. Geneva: World Health Organization; 2010.
6. Dheda K, Gumbo T, Gandhi NR et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis 2014;2:321-38.
7. Branch A. The Most Recent Experiments with "Bacille Calmette Guerin". The Most Recent Experiments with "Bacille Calmette Guerin" 1927;17:720-1.
8. Hesseling AC, Schaaf HS, Victor T et al. Resistant Mycobacterium bovis Bacillus Calmette-Guerin disease: implications for management of Bacillus Calmette-Guerin Disease in human immunodeficiency virus-infected children. Resistant Mycobacterium bovis Bacillus Calmette-Guerin disease: implications for management of Bacillus Calmette-Guerin Disease in human immunodeficiency virus-infected children 2004;23:476-9.
9. Hatherill M. Prospects for elimination of childhood tuberculosis: the role of new vaccines. Prospects for elimination of childhood tuberculosis: the role of new vaccines 2011;96:851-6.
10. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis 1993;22:1154-8.
11. Colditz GA, Berkey CS, Mosteller F et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature 1995;96:29-35.
12. Colditz GA, Brewer TF, Berkey CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Efficacy of BCG vaccine in the prevention of tuberculosis 1994;271:698-702.
13. Rodrigues LC, Pereira SM, Cunha SS et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial 2005;366:1290-5.
14. Dourado I, Rios MH, Pereira SM et al. Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren. Rates of adverse reactions to first and second doses of BCG vaccination: results of a large community trial in Brazilian schoolchildren 2003;7:399-402.
15. Cooper AM. Cell-mediated immune responses in tuberculosis. Cell-mediated immune responses in tuberculosis 2009;27:393-422.
16. Flynn JL, Chan J. Immunology of tuberculosis. Immunology of tuberculosis 2001;19:93-129.
17. North RJ, Jung YJ. Immunity to tuberculosis. Immunity to tuberculosis 2004;22:599-623.
18. Orme IM, Andersen P, Boom WH. T cell response to Mycobacterium tuberculosis. T cell response to Mycobacterium tuberculosis 1993;167:1481-97.
19. Orme IM, Miller ES, Roberts AD et al. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection. T lymphocytes mediating protection and cellular cytolysis during the course of Mycobacterium tuberculosis infection 1992;148:189-96.
20. Chackerian AA, Perera TV, Behar SM. Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis. Gamma interferon-producing CD4+ T lymphocytes in the lung correlate with resistance to infection with Mycobacterium tuberculosis 2001; 69:2666-74.
21. Jung YJ, Ryan L, LaCourse R, North RJ. Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice. Properties and protective value of the secondary versus primary T helper type 1 response to airborne Mycobacterium tuberculosis infection in mice 2005;201:1915-24.
22. Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management 2003;3:148-55.
23. Flynn JL, Goldstein MM, Chan J et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice 1995;2:561-72.
24. Flynn JL, Chan J, Triebold KJ et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection 1993;178:2249-54.
25. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. Tuberculosis in patients with human immunodeficiency virus infection 1999;340:367-73.
26. Lindenstrom T, Knudsen NP, Agger EM, Andersen P. Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells. Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells 2013;190:6311-9.
27. Sousa AO, Mazzaccaro RJ, Russell RG et al. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice 2000; 97:4204-8.
28. van Pinxteren LA, Cassidy JP, Smedegaard BH et al. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells 2000;30:3689-98.
29. Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis 2012;92(Suppl 1):S6-13.
30. Tameris MD, Hatherill M, Landry BS et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial 2013;381:1021-8.
31. Arbues A, Aguilo JI, Gonzalo-Asensio J et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M 2013;31:4867-73.
32. Grode L, Seiler P, Baumann S et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin 2005;115:2472-9.
33. Grode L, Ganoza CA, Brohm C et al. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial 2013;31:1340-8.
34. McShane H, Hill A. Prime-boost immunisation strategies for tuberculosis. Prime-boost immunisation strategies for tuberculosis 2005;7:962-7.
35. Xing Z, Charters TJ. Heterologous boost vaccines for bacillus Calmette-Guerin prime immunization against tuberculosis. Heterologous boost vaccines for bacillus Calmette-Guerin prime immunization against tuberculosis 2007;6:539-46.
36. Vordermeier HM, Rhodes SG, Dean G et al. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin 2004;112:461-70.
37. Schneider J, Gilbert SC, Blanchard TJ et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara 1998;4:397-402.
38. McShane H, Brookes R, Gilbert SC, Hill AV. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis. Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis 2001;69:681-6.
39. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L et al. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6 2001;69:2773-8.
40. Dietrich J, Aagaard C, Leah R et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy 2005;174:6332-9.
41. Billeskov R, Elvang TT, Andersen PL, Dietrich J. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity 2012;7:e39909.
42. Montoya J, Solon JA, Cunanan SR et al. A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. A randomized, controlled dose-finding Phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults 2013;33:1360-75.
43. Thacher EG, Cavassini M, Audran R et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial 2014;28:1769-81.
44. Bertholet S, Ireton GC, Ordway DJ et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis 2010;2:53ra74.
45. McShane H, Pathan AA, Sander CR et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans 2004;10:1240-4.
46. Radosevic K, Wieland CW, Rodriguez A et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon 2007;75:4105-15.
47. Abel B, Tameris M, Mansoor N et al. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults 2010;181:1407-17.
48. Santosuosso M, McCormick S, Zhang X et al. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis 2006;74:4634-43.
49. Wang J, Thorson L, Stokes RWet al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis 2004;173:6357-65.
50. Smaill F, Jeyanathan M, Smieja M et al. A human type 5 adenovirusbased tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. A human type 5 adenovirusbased tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity 2013;5:205ra134.
51. Rowland R, Pathan AA, Satti I et al. Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial. Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial 2013;9:50-62.
52. Thorner AR, Vogels R, Kaspers J et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa 2006;44:3781-3.
53. Sander CR, Pathan AA, Beveridge NE et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosisinfected individuals. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosisinfected individuals 2009;179:724-33.
54. Minassian AM, Rowland R, Beveridge NE et al. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults 2011;1:e000223.
55. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland 2004;350:896-903.
56. Lewis DJ, Huo Z, Barnett S et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin 2009;4:e6999.
57. Low N, Kraemer S, Schneider M, Restrepo AM. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis. Immunogenicity and safety of aerosolized measles vaccine: systematic review and meta-analysis 2008;26:383-98.
58. Hiremath GS, Omer SB. A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration. A meta-analysis of studies comparing the respiratory route with the subcutaneous route of measles vaccine administration 2005;1:30-6.
59. Dilraj A, Cutts FT, de Castro JF et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomised trial 2000;355:798-803.
60. Dilraj A, Sukhoo R, Cutts FT, Bennett JV. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination. Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination 2007;25:4170-4.
61. WHO. Global Health Observatory: Measles Immunization Coverage. Geneva: World Health Organization; 2014.
62. Markowitz LE, Albrecht P, Orenstein WA et al. Persistence of measles antibody after revaccination. Persistence of measles antibody after revaccination 1992;166:205-8.
63. Cohn ML, Robinson ED, Faerber M et al. Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults. Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults 1994;13:34-8.
64. Diaz-Ortega JL, Bennett JV, Castaneda-Desales D et al. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection. Booster immune response in children 6-7 years of age, randomly assigned to four groups with two MMR vaccines applied by aerosol or by injection 2014;32:3680-6.
65. Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age:a meta-analysis of 8 randomized controlled studies. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age:a meta-analysis of 8 randomized controlled studies 2012;30:886-92.
66. Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination 2010;29:806-11.
67. Barclay WR, Busey WM, Dalgard DW et al. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin 1973;107:351-8.
68. Chen L, Wang J, Zganiacz A, Xing Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis 2004;72:238-46.
69. Garcia-Contreras L, Wong YL, Muttil P et al. Immunization by a bacterial aerosol. Immunization by a bacterial aerosol 2008;105:4656-60.
70. Gheorghiu M. BCG-induced mucosal immune responses. BCG-induced mucosal immune responses 1994;16:435-44.
71. Giri PK, Verma I, Khuller GK. Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice 2006;53:350-6.
72. Santosuosso M, Zhang X, McCormick S et al. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen 2005;174:7986-94.
73. Vordermeier HM, Huygen K, Singh M et al. Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing Mycobacterial antigen 85A and Mycobacterium bovis BCG. Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing Mycobacterial antigen 85A and Mycobacterium bovis BCG 2006;74:1416-8.
74. Goonetilleke NP, McShane H, Hannan CM et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara 2003;171:1602-9.
75. White AD, Sibley L, Dennis MJ et al. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques 2013;20:663-72.
76. Darrah PA, Bolton DL, Lackner AA et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacteriumtuberculosis challenge. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacteriumtuberculosis challenge 2014;193:1799-811.
77. Reljic R, Sibley L, Huang JM et al. Mucosal vaccination against tuberculosis using inert bioparticles. Mucosal vaccination against tuberculosis using inert bioparticles 2013;81:4071-80.
78. Rosenthal SR, McEnery JT, Raisys N. Aerogenic BCG vaccination against tuberculosis in animal and human subjects. Aerogenic BCG vaccination against tuberculosis in animal and human subjects 1968;5:309-23.
79. Satti I, Meyer J, Harris SA et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial 2014;14:939-46.
80. Skaria S, Smaldone GC. Omron NE U22: Comparison between vibrating mesh and jet nebulizer. Omron NE U22: Comparison between vibrating mesh and jet nebulizer 2010;23:173-80.
81. Koch R. A Further communication on a remedy for tuberculosis. A Further communication on a remedy for tuberculosis 1891;1:125-7.
82. Fourie PB, Germishuizen WA, Wong YL, Edwards DA. Spray drying TB vaccines for pulmonary administration. Spray drying TB vaccines for pulmonary administration 2008;8:857-63.
83. Brown M, Varia H, Bassett P et al. Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate 2007;44:1415-20.
84. Brightling CE. Sputum induction in asthma: a research technique or a clinical tool? Chest 2006;29:503-4.
85. Pin I, Freitag AP, O'Byrne PM et al. Changes in the cellular profile of induced sputum after allergen-induced asthmatic responses. Changes in the cellular profile of induced sputum after allergen-induced asthmatic responses 1992;145:1265-9.
86. Pin I, Gibson PG, Kolendowicz R et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Use of induced sputum cell counts to investigate airway inflammation in asthma 1992;47:25-9.
87. Vieira MO, Pizzichini E, Steidle LJ et al. Sputum induction in severe exacerbations of asthma: safety of a modified method. Sputum induction in severe exacerbations of asthma: safety of a modified method 2011;38:979-80.